MENU
+Compare
AUPH
Stock ticker: NASDAQ
AS OF
Oct 6 closing price
Price
$11.32
Change
-$0.03 (-0.26%)
Capitalization
1.49B

AUPH Aurinia Pharmaceuticals Forecast, Technical & Fundamental Analysis

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs... Show more

Industry: #Biotechnology
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AUPH with price predictions
Oct 06, 2025

Momentum Indicator for AUPH turns negative, indicating new downward trend

AUPH saw its Momentum Indicator move below the 0 level on September 29, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned negative. In of the 100 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

AUPH moved below its 50-day moving average on September 29, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AUPH's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where AUPH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

AUPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 162 cases where AUPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.444) is normal, around the industry mean (23.464). P/E Ratio (26.326) is within average values for comparable stocks, (54.589). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.244). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (6.289) is also within normal values, averaging (345.477).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AUPH is expected to report earnings to fall 8.31% to 14 cents per share on October 30

Aurinia Pharmaceuticals AUPH Stock Earnings Reports
Q3'25
Est.
$0.15
Q2'25
Beat
by $0.02
Q1'25
Beat
by $0.05
Q4'24
Missed
by $0.02
Q3'24
Beat
by $0.08
The last earnings report on July 31 showed earnings per share of 15 cents, beating the estimate of 14 cents. With 1.45M shares outstanding, the current market capitalization sits at 1.49B.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
14315 118 Avenue
Phone
+1 250 708-4272
Employees
300
Web
https://www.auriniapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCDCX23.430.14
+0.60%
BlackRock Emerging Mkts Inv C
SUVAX13.11N/A
N/A
PGIM Quant Solutions Large-Cap Val A
FAMEX59.19N/A
N/A
FAM Dividend Focus Fund Investor
FFIMX22.66N/A
N/A
Fidelity Advisor Asset Manager 50% I
WGLSX12.43N/A
N/A
Wasatch Long/Short Alpha Institutional

AUPH and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
-0.26%
JSPR - AUPH
44%
Loosely correlated
-3.61%
MLTX - AUPH
42%
Loosely correlated
+2.73%
VCYT - AUPH
39%
Loosely correlated
+0.11%
KALA - AUPH
38%
Loosely correlated
-1.30%
LRMR - AUPH
38%
Loosely correlated
-1.23%
More

Groups containing AUPH

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
-0.26%
drugs
theme (233 stocks)
40%
Loosely correlated
+0.26%
biotechnology
theme (218 stocks)
37%
Loosely correlated
+0.14%
north america
theme (156 stocks)
32%
Poorly correlated
+0.74%
cancer
theme (78 stocks)
28%
Poorly correlated
+0.19%
biopharmaceuticals
theme (47 stocks)
27%
Poorly correlated
+1.10%